|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0019704,
umls-concept:C0020971,
umls-concept:C0021400,
umls-concept:C0039194,
umls-concept:C0042216,
umls-concept:C0085358,
umls-concept:C0205195,
umls-concept:C0871261,
umls-concept:C1332717,
umls-concept:C1413244,
umls-concept:C1514798,
umls-concept:C1704632,
umls-concept:C1706438,
umls-concept:C1706817,
umls-concept:C2349975,
umls-concept:C2698600,
umls-concept:C2911692
|
|
pubmed:issue |
7-8
|
|
pubmed:dateCreated |
1999-5-27
|
|
pubmed:abstractText |
With the aim to determine if immunization with two different live recombinant viral vectors could lead to an enhancement of the cellular immune response to HIV-1 antigens, we have characterized the CD8+ T cell response elicited against the V3 loop epitope from HIV-1 env protein in Balb/c mice immunized with either: a recombinant influenza virus (Flu-Env) expressing the V3 loop epitope from HIV-1 strain IIIB, a vaccinia virus recombinant (VV-Env) expressing the complete HIV-1-IIIB env protein, or a combination of both. The CD8+ T cell response, measured by the ELISPOT assay, in animals primed with Flu-Env and boosted with VV-Env was 5 to 6 times higher than in animals inoculated with either Flu-Env or VV-Env alone. Similar results were obtained with recombinant viruses expressing the V3 loop epitope or the complete env protein, respectively, from the MN strain of HIV-1. Our results indicate that the use of two different live vectors for priming and boosting has a synergistic effect on the immune response against HIV-1, and could represent a novel vaccination strategy against AIDS.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes, T-Lymphocyte,
http://linkedlifedata.com/resource/pubmed/chemical/Gene Products, env,
http://linkedlifedata.com/resource/pubmed/chemical/Influenza Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Combined,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Synthetic,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Vaccines
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0264-410X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
26
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
887-92
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:10067695-Amino Acid Sequence,
pubmed-meshheading:10067695-Animals,
pubmed-meshheading:10067695-CD8-Positive T-Lymphocytes,
pubmed-meshheading:10067695-Epitopes, T-Lymphocyte,
pubmed-meshheading:10067695-Gene Products, env,
pubmed-meshheading:10067695-HIV-1,
pubmed-meshheading:10067695-Humans,
pubmed-meshheading:10067695-Immunization, Secondary,
pubmed-meshheading:10067695-Influenza Vaccines,
pubmed-meshheading:10067695-Interferon-gamma,
pubmed-meshheading:10067695-Lymphocyte Activation,
pubmed-meshheading:10067695-Mice,
pubmed-meshheading:10067695-Mice, Inbred BALB C,
pubmed-meshheading:10067695-Molecular Sequence Data,
pubmed-meshheading:10067695-Vaccines, Combined,
pubmed-meshheading:10067695-Vaccines, Synthetic,
pubmed-meshheading:10067695-Vaccinia virus,
pubmed-meshheading:10067695-Viral Vaccines
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants.
|
|
pubmed:affiliation |
Department of Cellular and Molecular Biology, Centro Nacional de Biotecnología, (CSIC), Campus Universidad Autónoma, Madrid, Spain.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
